Utility analysis.

Utility analysis is shown for intermediate-risk patients, assuming that QOL during Tox1 was better for chemotherapy than for ASCT (uTox1 for ASCT ranging from 0 to 0.5) and that QOL during Tox2 was better for ASCT than for chemotherapy (uTox2 respectively set to 0.75 and 0.5). Dashed lines indicate same amount of Q-TWiST (eg, line −3 indicates ASCT provides 3 fewer months than chemotherapy). Letters refer to examples given in text.